Please click on the link to see a list of melanoma journal citations the crossed the MRV desk this month.
Publications
FDA Will Review Application Seeking Expansion of Keytruda’s Dosing Schedule
The U.S. Food and Drug Administration (FDA) has accepted for review six supplemental biologics license applications (sBLAs) seeking to expand the dosing schedule of Keytruda (pembrolizumab) so the medication can be administered every six weeks.
Pembrolizumab vs ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Researchers describe findings after a 5-year follow-up among participants of an open-label, multicenter, randomized, controlled, phase 3 study assessing pembrolizumab vs ipilimumab in patients with advanced melanoma.
Melanoma Journal Articles for June 2019
Please click on the link to see a list of melanoma journal citations the crossed the MRV desk this month.